Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Chinese commission reviewing drug pricing

China's National Development and Reform Commission (NDRC) is reviewing drug pricing and manufacturing costs for 60 Chinese and international

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE